Madrigalв Dip Apr 2026

Madrigal continues to report positive results from its own clinical trials, including the trial.

: Experts believe the U.S. market has approximately 1.5 million diagnosed MASH patients, providing "plenty of room" for multiple treatments, including Madrigal’s Rezdiffra. Clinical & Operational Status MadrigalВ Dip

: Analysts at Piper Sandler recently raised their price target for Madrigal to $400 (up from $336), viewing the competitor data as validation for the entire MASH treatment market rather than a threat. Madrigal continues to report positive results from its

: Akero's results showed the potential for cirrhosis reversal, which temporarily overshadowed Madrigal's market position. Clinical & Operational Status : Analysts at Piper

The consensus among firms like TipRanks is that Madrigal’s treatment could become a "blockbuster," supported by its first-mover advantage in the space.

The "dip" was primarily triggered by releasing positive Phase 2b data for its drug efruxifermin in patients with compensated cirrhosis due to MASH (metabolic dysfunction-associated steatohepatitis).

: Evercore ISI explicitly labeled the dip as a Buying Opportunity , maintaining an "Outperform" rating with a price target of $392 .